Australia · Delayed Price · Currency is AUD Nexsen Company Description
Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications.
The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones.
It also offers rapid diagnostic programs targeting traumatic brain injury and neonatal sepsis. In addition, it is involved in developing rapid dual sensors for the detection of E.coli and Salmonella.
The company was incorporated in 2021 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mark Muzzin |
Contact Details
Address: 4 Bridge Street Sydney, NSW 2000 Australia | |
| Phone | 61 2 9174 5388 |
| Website | nexsen.bio |
Stock Details
| Ticker Symbol | NXN |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000418782 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Reece O'Connell | Executive Chairman |
| Mark Anthony Muzzin B.A. | Founder, MD, Advisory Board Member and Director |
| Richard Mark Jarvis | Chief Financial Officer |
| Dr. Sanje Mahasivam | Research Team Leader and Chief Technology Officer |
| Prof. Vipul Bansal | Chief Innovation Officer and Advisory Board Chair |
| Sonny Didugu | Company Secretary |